Actinogen Medical Limited ASX: ACW Share Price & Review

ACW Overview

ACW Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ACW

Website

Actinogen Medical Limited

Telephone

61.2.8964.7401

Address

Level 9 Suite 901 109 Pitt Street Sydney, New South Wales (NSW) 2000

Description

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company was founded by Geoff E. D. Brooke & David Keast on March 23, 1999 and is headquartered in Sydney, Australia.

ACW Price Chart

Key Stats

Market Cap

AU$69.90M

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.1

Trade Value (12mth)

AU$79,725.00

1 week

9.52%

1 month

9.52%

YTD

-11.54%

1 year

-64.62%

All time high

0.84

Key Fundamentals

EPS 3 yr Growth

130.80%

EBITDA Margin

N/A

Operating Cashflow

-$17m

Free Cash Flow Return

-101.60%

ROIC

-78.20%

Interest Coverage

-937.40

Quick Ratio

13.90

Other Data

Shares on Issue (Fully Dilluted)

2917m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ACW Announcements

Latest Announcements

Date	Announcements
30 June 25	ACW 100th AD trial participant & interim analysis timeline × ACW 100th AD trial participant & interim analysis timeline
30 June 25	ACW accesses up to $13.8m in non-dilutive R&D tax funding × ACW accesses up to $13.8m in non-dilutive R&D tax funding
16 June 25	ACW presents at BIO international partnering conference × ACW presents at BIO international partnering conference
21 May 25	Ceasing to be a substantial holder × Ceasing to be a substantial holder
19 May 25	Actinogen CMO presents positive depression data at APA 2025 × Actinogen CMO presents positive depression data at APA 2025
15 May 25	ACW Science Forum today - Preparing for commercialization × ACW Science Forum today - Preparing for commercialization
30 April 25	Actinogen March 2025 quarterly activity report & Appendix 4C × Actinogen March 2025 quarterly activity report & Appendix 4C
24 April 25	ACW Science Forum notice - Preparing for commercialization × ACW Science Forum notice - Preparing for commercialization
23 April 25	Change in substantial holding × Change in substantial holding
02 April 25	ACW CMO presents Xanamem pTau poster at ADPD25 conference × ACW CMO presents Xanamem pTau poster at ADPD25 conference
27 March 25	ACW conducts Type C meeting with FDA regarding depression × ACW conducts Type C meeting with FDA regarding depression
26 March 25	Actinogen presentation to ASX small & mid-caps conference × Actinogen presentation to ASX small & mid-caps conference
24 March 25	Application for quotation of securities - ACW × Application for quotation of securities - ACW
24 March 25	Notification of cessation of securities - ACW × Notification of cessation of securities - ACW
24 March 25	Notification of cessation of securities - ACW × Notification of cessation of securities - ACW
24 March 25	Appendix 3Ys x 5 × Appendix 3Ys x 5
14 March 25	Results of Meeting × Results of Meeting
04 March 25	Notification of buy-back - ACW × Notification of buy-back - ACW
24 February 25	Actinogen HY2025 financial report and Appendix 4D × Actinogen HY2025 financial report and Appendix 4D
24 February 25	ACW HY25 results Advancing to latestage clinical development × ACW HY25 results Advancing to latestage clinical development
10 February 25	Letter to Shareholders, Notice of GM & Proxy Form × Letter to Shareholders, Notice of GM & Proxy Form
06 February 25	Peer-reviewed clinpharm manuscript published × Peer-reviewed clinpharm manuscript published
30 January 25	Application for quotation of securities - ACW × Application for quotation of securities - ACW
29 January 25	ACW December 2024 quarterly activity report & Appendix 4C × ACW December 2024 quarterly activity report & Appendix 4C
13 January 25	ACW presents at Sachs Neuro & WHO grants INN emestedastat × ACW presents at Sachs Neuro & WHO grants INN emestedastat

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Falling Divs over next 2

Values and Recommendations

Key Stats

Consensus Score

Recommendation

EPS 1 month Change

Quality Yield

Falling Divs over next 2

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ACW Shortsell

Frequently Asked Questions

What is the current share price of Actinogen Medical Limited (ACW:ASX)?

The current share price of Actinogen Medical Limited (ACW:ASX) is AU$0.023.

What is the 52-week high share price for Actinogen Medical Limited (ACW:ASX)?

The 52-week high share price for Actinogen Medical Limited (ACW:ASX) is AU$0.10.

What is the 52-week low share price for Actinogen Medical Limited (ACW:ASX)?

The 52-week low share price for Actinogen Medical Limited (ACW:ASX)? is AU$0.02.

What is the dividend yield for Actinogen Medical Limited (ACW:ASX)?

Actinogen Medical Limited (ACW:ASX) does not pay a dividend.

What was Actinogen Medical Limited (ACW:ASX) last dividend payment?

Actinogen Medical Limited (ACW:ASX) does not pay a dividend.

What is the franking level for Actinogen Medical Limited (ACW:ASX)?

Actinogen Medical Limited (ACW:ASX) has a franking level of 0.0%.

In which sector is Actinogen Medical Limited (ACW:ASX) classified?

Actinogen Medical Limited (ACW:ASX) is classified in the Healthcare.

The current P/E ratio for Actinogen Medical Limited (ACW:ASX) is .